Table 1 Patient characteristics in year 1 cohort, overall and according to occurrence of estradiol level > 2.72 pg/mL at 1 year

From: Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy

Characteristic

N (%)

P

Overall (N = 84)

E2 ≤ 2.72 pg/mL (N = 38)

E2 > 2.72 pg/mL (N = 46)

Age at diagnosis, years

    

 ≤ 30

10 (11.9)

2 (5.3)

8 (17.4)

0.075

 31–35

28 (33.3)

17 (44.7)

11 (23.9)

 

 36–40

46 (54.8)

19 (50.0)

27 (58.7)

 

Race

    

 White

77 (91.6)

36 (94.7)

41 (89.1)

0.999

 Asian

5 (6.0)

2 (5.3)

3 (6.5)

 

 Black

1 (1.2)

0 (0)

1 (2.2)

 

 Other

1 (1.2)

0 (0)

1 (2.2)

 

BMI at diagnosis, kg/m2

    

 < 18.5

3 (3.6)

3 (7.9)

0

0.120

 18.5–24.9

50 (59.5)

23 (60.5)

27 (58.7)

 

 ≥ 25

27 (32.1)

10 (26.3)

17 (37.0)

 

 Missing

4 (4.8)

2 (5.3)

2 (4.3)

 

Smoking history

   

0.158

 Active/former

28 (33.3)

9 (23.7)

19 (41.3)

 

 Never

53 (63.1)

27 (71.0)

26 (56.5)

 

 Missing

3 (3.6)

2 (5.3)

1 (2.2)

 

Alcohol history

   

0.448

 Active

54 (64.3)

8 (21.0)

16 (34.8)

 

 Former

24 (28.6)

27 (71.1)

27 (58.7)

 

 Never

2 (2.4)

1 (2.6)

1 (2.2)

 

 Missing

4 (4.8)

2 (5.3)

2 (4.3)

 

Stage

   

0.474

 I

23 (27.4)

8 (21.0)

15 (32.6)

 

 II

38 (45.2)

18 (47.4)

20 (43.5)

 

 III

11 (13.1)

7 (18.4)

4 (8.7)

 

 IV

12 (14.3)

5 (13.2)

7 (15.2)

 

HER2 status

   

0.277

 Negative

67 (79.8)

28 (73.7)

39 (84.8)

 

 Positive

17 (20.2)

10 (26.3)

7 (15.2)

 

Prior chemotherapy

   

0.045

 No

35 (41.7)

11 (29.0)

24 (52.2)

 

 Yes

49 (58.3)

27 (71.1)

22 (47.8)

 

Chemotherapy regimen*

   

0.152

 Anthracycline plus taxane

29 (59.2)

17 (63.0)

12(54.5)

 

 Anthracycline-based

6 (12.2)

5 (18.5)

1 (4.5)

 

 Taxane-based

14 (29.0)

5 (18.5)

9 (40.9)

 

GnRHa drug

   

0.174

 Leuprolide

64 (76.2)

28 (73.7)

36 (78.3)

 

 Goserelin

14 (16.7)

5 (13.2)

9 (19.6)

 

 Triptorelin

6 (7.1)

5 (13.2)

1 (2.2)

 

GNRHa schedule

   

0.485

 Every month

47 (56.0)

23 (60.5)

24 (52.2)

 

 Every 3 months

34 (40.5)

13 (34.2)

21 (45.6)

 

 Unknown

3 (3.6)

2 (5.3)

1 (2.2)

 

Endocrine therapy

   

0.009

 Tamoxifen

59 (70.2)

21 (55.3)

38 (82.6)

 

 Aromatase inhibitor

25 (29.8)

17 (44.7)

8 (17.4)

 
  1. *± Trastuzumab ± pertuzumab in patients with HER2-positive breast cancer.
  2. E2 estradiol, BMI body mass index, HER2 human epidermal growth factor 2 receptor, GnRHa gonadotropin-releasing hormone agonist.
Back to article page